PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY CATEGORY
• Segmentation by category
• Comparison by category
• Global ankylosing spondylitis treatment market – Market size and forecast 2017-2022
• Global non-radiographic axial spondyloarthritis treatment market – Market size and forecast 2017-2022
• Market opportunity by category

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Pfizer
• UCB

PART 16: APPENDIX
• List of abbreviations

List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global axial spondyloarthritis treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global axial spondyloarthritis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global axial spondyloarthritis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2018
Exhibit 19: Key clinical trial candidates of axial spondyloarthritis 2017-2018
Exhibit 20: Global axial spondyloarthritis treatment market by category– Market share 2017-2022 (%)
Exhibit 21: Comparison by category
Exhibit 22: Global ankylosing spondylitis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global ankylosing spondylitis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global non-radiographic axial spondyloarthritis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global non-radiographic axial spondyloarthritis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by category
Exhibit 27: Customer landscape
Exhibit 28: Global axial spondyloarthritis treatment market by geography – Market share 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in the Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: AbbVie: Overview
Exhibit 46: AbbVie – Business segments
Exhibit 47: AbbVie – Organizational developments
Exhibit 48: AbbVie – Geographic focus
Exhibit 49: AbbVie – Key offerings
Exhibit 50: AbbVie – Key customers
Exhibit 51: Amgen: Overview
Exhibit 52: Amgen – Business segments
Exhibit 53: Amgen – Organizational developments
Exhibit 54: Amgen – Geographic focus
Exhibit 55: Amgen – Key offerings
Exhibit 56: Amgen – Key customers
Exhibit 57: Johnson & Johnson: Overview
Exhibit 58: Johnson & Johnson– Business segments
Exhibit 59: Johnson & Johnson– Organizational developments
Exhibit 60: Johnson & Johnson– Geographic focus
Exhibit 61: Johnson & Johnson– Segment focus
Exhibit 62: Johnson & Johnson– Key offerings
Exhibit 63: Johnson & Johnson– Key customers
Exhibit 64: Pfizer: Overview
Exhibit 65: Pfizer – Business segments
Exhibit 66: Pfizer – Organizational developments
Exhibit 67: Pfizer – Geographic focus
Exhibit 68: Pfizer– Segment focus
Exhibit 69: Pfizer – Key offerings
Exhibit 70: Pfizer – Key customers
Exhibit 71: UCB: Overview
Exhibit 72: UCB – Business segments
Exhibit 73: UCB – Organizational developments
Exhibit 74: UCB – Geographic focus
Exhibit 75: UCB – Key offerings
Exhibit 76: UCB – Key customers

Companies Mentioned
. AbbVie
. Amgen
. Johnson & Johnson
. Pfizer
. UCB